Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer (NCT06463028)
An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Who can join: Review the eligibility criteria below.
Location: UC San Diego Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- UC San Diego Moores Cancer Center — La Jolla, California
- University of California, San Francisco (UCSF) — San Francisco, California
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- Florida Cancer Specialists, North — St. Petersburg, Florida
- Florida Cancer Specialists, East — West Palm Beach, Florida
- Maryland Oncology Hematology, P.A. — Brandywine, Maryland
- Minnesota Oncology Hematology, P.A. — Maple Grove, Minnesota
- Women's Cancer Care Associates, LLC — Albany, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Oncology Associates of Oregon, P.C. — Eugene, Oregon
- Northwest Cancer Specialists, P.C. — Portland, Oregon
- Alliance Cancer Specialists, PC — Doylestown, Pennsylvania
- West Penn Hospital — Pittsburgh, Pennsylvania
- Avera Cancer Institute — Sioux Falls, South Dakota
- Texas Oncology - West Texas — El Paso, Texas
- Texas Oncology - Gulf Coast — The Woodlands, Texas
- Virginia Cancer Specialists, P.C. — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (708) 406-9282
Email: clinicaltrials@faeththerapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Cancer
- Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation — Lexington, Kentucky
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Mobile, Alabama
- Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer — Houston, Texas
- A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer — Little Rock, Arkansas
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line — Garran,
- Activity and Cancer Survivorship Exercise Pilot — Iowa City, Iowa
Explore by condition: All Endometrial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.